A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2004
12/23/2004	US20040258619 Diaminedioxime radiometal complexes
12/23/2004	US20040258616 Compositions and methods for treating cancer using IGSF9 and LIV-1
12/23/2004	DE3790581B4 Verfahren zur selektiven Vernichtung von hypoxischen Tumorzellen Process for the selective destruction of hypoxic tumor cells
12/23/2004	DE10326186A1 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Bicyclic heterocycles, pharmaceutical compositions containing them, their use and process for their preparation
12/23/2004	DE10323898A1 Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe Hydroxyamidine and hydroxyguanidine compounds as inhibitors of urokinase
12/23/2004	CA2737127A1 Maytansinoid-antibody conjugate compositions
12/23/2004	CA2569585A1 Compositions for oral administration of campothecin and its analogs
12/23/2004	CA2563361A1 Cell permeable conjugates of peptides for inhibition of protein kinases
12/23/2004	CA2529496A1 Anti-cd74 immunoconjugates and methods
12/23/2004	CA2529090A1 2-aminopyrimidine derivatives as raf kinase inhibitors
12/23/2004	CA2528929A1 Cyclic tertiary amine compound
12/23/2004	CA2528844A1 Novel phosphorylated sequences of the phosphatase cdc25b, antibodies for said sequences and use thereof
12/23/2004	CA2528433A1 Thiadiazoline derivative
12/23/2004	CA2528382A1 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them
12/23/2004	CA2528186A1 Molecules for targeting and releasing therapeutic compounds, and the use thereof
12/23/2004	CA2527621A1 Method of inhibiting tumor growth with anti-tissue factor antibodies
12/23/2004	CA2527591A1 Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors
12/23/2004	CA2527246A1 Aniline derivatives
12/23/2004	CA2527236A1 Thiotungstate analogues and uses thereof
12/23/2004	CA2526217A1 Heteroaryl-fused pyrimidinyl compounds as anticancer agents
12/23/2004	CA2526041A1 Anthranylamide pyridones that inhibit vegfr-2 and vegfr-3
12/23/2004	CA2519875A1 Method of tumor regression with vegf inhibitors
12/23/2004	CA2515369A1 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
12/23/2004	CA2514288A1 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
12/23/2004	CA2494704A1 Radioactively labelled amino acid analogues, their preparation and use
12/22/2004	EP1489189A1 Diagnostics and remedies for malignant brain tumor
12/22/2004	EP1489187A1 Osteoclast differentiation inhibitors
12/22/2004	EP1489186A1 Angiogenesis inhibitors
12/22/2004	EP1489185A1 Methods and compositions for use in splicesome mediated rna trans-splicing
12/22/2004	EP1489183A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
12/22/2004	EP1489177A1 Cdc7-ask kinase complex, substrate of the kinase complex, antibody specific to the substrate, and method of screening compound capable of inhibiting cdc7-ask kinase using the same
12/22/2004	EP1489172A1 Nuclear receptor err gamma 3
12/22/2004	EP1489171A1 Functional molecule and process for producing the same
12/22/2004	EP1489169A1 Sumo inhibitors
12/22/2004	EP1489096A1 Novel hemepeptide
12/22/2004	EP1488809A1 Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
12/22/2004	EP1488807A1 Remedies for sex hormone-dependent disease
12/22/2004	EP1488796A1 Ameliorant for chemical treatment of cancer
12/22/2004	EP1488795A1 Remedies for lung cancer
12/22/2004	EP1488792A2 Quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
12/22/2004	EP1488239A2 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
12/22/2004	EP1487992A2 Central airway administration for systemic delivery of therapeutics
12/22/2004	EP1487991A2 Cancer-linked gene as target for chemotherapy
12/22/2004	EP1487984A1 Dna vaccines encoding cea and a cd40 ligand and methods of use thereof
12/22/2004	EP1487983A2 Prevention of recurrence and metastasis of cancer
12/22/2004	EP1487981A2 Growth regulating proteins
12/22/2004	EP1487879A2 Bispecific antibody point mutations for enhancing rate of clearance
12/22/2004	EP1487877A2 Compositions and methods for the diagnosis and treatment of tumor
12/22/2004	EP1487876A1 The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
12/22/2004	EP1487857A1 Lymphatic and blood endothelial cell genes
12/22/2004	EP1487856A2 Human antibodies specific to kdr and uses thereof
12/22/2004	EP1487842A1 An optically acitve pyridine derivative and a medicament containing the same
12/22/2004	EP1487841A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
12/22/2004	EP1487840A1 Crystalline polymorphic form of irinotecan hydrochloride
12/22/2004	EP1487827A1 Anti-inflammatory morpholin-acetamide derivatives
12/22/2004	EP1487824A1 Diamino-pyrimidines and their use as angiogenesis inhibitors
12/22/2004	EP1487823A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity
12/22/2004	EP1487819A2 Azepane derivatives and their use as atk1 inhibitors
12/22/2004	EP1487813A1 Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
12/22/2004	EP1487811A1 N-sulfonylurea apoptosis promoters
12/22/2004	EP1487807A2 New compounds
12/22/2004	EP1487806A1 4-anilino quinazoline derivatives as antiproliferative agents
12/22/2004	EP1487805A1 Pyrimidine derivatives
12/22/2004	EP1487804A2 Aminoindazole derivatives as protein-kinase inhibitors
12/22/2004	EP1487803A1 Indazoles substituted with an anti-cancerous activity
12/22/2004	EP1487800A1 Phenanthridinones as parp inhibitors
12/22/2004	EP1487799A1 9-aminoacridine derivatives and process for the preparation thereof
12/22/2004	EP1487793A1 Piperidine derivatives useful as modulators of chemokine receptor activity
12/22/2004	EP1487783A2 Irreversible selective androgen receptor modulators and methods of use thereof
12/22/2004	EP1487501A2 A phosphatase associated with metastasis
12/22/2004	EP1487495A1 Combination comprising a cdk inhibitor and doxorubicin
12/22/2004	EP1487493A2 Conjugates of therapeutic or cytotoxic agents and biologically active peptides
12/22/2004	EP1487492A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
12/22/2004	EP1487490A2 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
12/22/2004	EP1487489A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN avb3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
12/22/2004	EP1487487A2 Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
12/22/2004	EP1487484A2 Use of mixtures of lipopeptides for vaccine production
12/22/2004	EP1487482A2 Dna vaccine against proliferating endothelial cells and methods of use thereof.
12/22/2004	EP1487477A2 Methods of using flt3-ligand in immunization protocols
12/22/2004	EP1487475A1 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
12/22/2004	EP1487463A2 Local production and/or delivery of anti-cancer agents by stromal cell precursors
12/22/2004	EP1487458A2 Multi-substitued selective androgen receptor modulators and methods of use thereof
12/22/2004	EP1487452A1 Use of 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl -benzamide for treating seminomas
12/22/2004	EP1487449A1 Tyrosyl derivatives and their use as p2x7 receptor modulators
12/22/2004	EP1487446A2 Bicyclic heterocycles for the treatment of diabetes and other diseases
12/22/2004	EP1487444A1 Use of pyridyl amides as inhibitors of angiogenesis
12/22/2004	EP1487443A1 Heterocyclic amide derivatives for the treatment of diabetes and other diseases
12/22/2004	EP1487439A1 Solubilization of weak bases
12/22/2004	EP1487436A1 Combination therapy for treating, preventing or managing proliferative disorders and cancers
12/22/2004	EP1487434A2 Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
12/22/2004	EP1487433A1 Anti-cancer combinations of dmxaa and a nsaid
12/22/2004	EP1487428A2 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
12/22/2004	EP1487426A2 Methods of inducing terminal differentiation
12/22/2004	EP1487412A1 Chemosensitizing with liposomes containing oligonucleotides
12/22/2004	EP1487410A2 Preparation of sterile stabilized nanodispersions
12/22/2004	EP1487402A1 New composition including a pigment assembly comprising a mica core
12/22/2004	EP1453949A4 Production of cell suspensions
12/22/2004	EP1436266A4 Methods and compositions of novel triazine compounds
12/22/2004	EP1406894B1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity
12/22/2004	EP1333719A4 Corticotropin releasing factor receptor 2 deficient mice and uses thereof

1 ... 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 ... 2211